PEPTOX
Financiado
An innovative peptide system for novel drugs targeting microbial Repeats In Toxi...
Despite progress in infection treatment in the last decades, the prevalence and mortality of infections still poses a heavy burden over humankind. The development of antimicrobial resistance and the rapid mutagenesis of bacteria t...
Despite progress in infection treatment in the last decades, the prevalence and mortality of infections still poses a heavy burden over humankind. The development of antimicrobial resistance and the rapid mutagenesis of bacteria that leads to inefficiency of vaccines, play an important role in maintaining infections high level of threat. Even diseases that have plagued us for centuries, such as cholera, still challenge medical professionals and cause a significant social cost. New therapeutic approaches that promise a higher success rate are a pressing need. We recently discovered a high similarity between an ice-binding protein and the RTX adhesin (FrhA) used by the bacteria of cholera to attach to and infect the human intestine. Moreover, we discovered compounds that bind to FrhA and successfully block it, suggesting these could help prevent cholera’s infection. If these can also detach already adhered bacteria, cholera could be effectively removed and cured. In this ERC PoC PEPTOX project, we aim to optimise the synthesis and characterization of the newly discovered compounds and demonstrate blockage of cholera adhesion in an in vitro cellular model.
ver más
Duración del proyecto: 34 meses
Fecha Inicio: 2020-01-30
Fecha Fin: 2022-11-30
Fecha Fin: 2022-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-11-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2019-POC:
ERC Proof of Concept Grant
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
TECHNISCHE UNIVERSITEIT EINDHOVEN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
205.81K€ |
Participante